Kendzerska, Tetyana http://orcid.org/0000-0002-5301-1796
Saad, Mysa
Ayas, Najib http://orcid.org/0000-0003-2742-6514
Robillard, Rebecca http://orcid.org/0000-0002-1491-997X
Funding for this research was provided by:
Physicians' Services Incorporated Foundation
Article History
Received: 13 November 2021
Revised: 4 March 2022
Accepted: 13 May 2022
First Online: 8 June 2022
Declarations
:
: All authors report that they have no conflicts of interest or financial conflicts related to this manuscript. T Kendzerska received a speaker honorarium from AstraZeneca Canada Inc. and is a Clinical Consultant at Pitolisant Medical Advisory Board (Paladin Labs Inc.).
: This study was approved by the Clinical Trials Ontario-Qualified Research Ethics Board (Protocol #2131) (ClinicalTrials.gov: NCT04369690).
: All participants consented to be included in the research before starting the survey.
Free to read: This content has been made available to all.